title: Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence.
abstract: OBJECTIVE
  Previous cost-effectiveness analyses of oxaliplatin have been based on randomised trials whereas current Dutch policy requires evidence from daily practice. The objective of this study was to examine the real-world cost-effectiveness of oxaliplatin plus fluoropyrimidines (FL) versus FL-only as adjuvant treatment of stage III colon cancer.
  
  
  METHODS
  A Markov model was developed to estimate lifetime cost and quality-adjusted life-years from a hospital perspective. The effectiveness of the oxaliplatin arm was modelled by combining published efficacy data from the pivotal clinical registration trial (MOSAIC trial) with real-world (RW) data from a Dutch population-based observational study. RW patients were categorised into "eligible" or "ineligible", depending on whether the patients fulfilled the MOSAIC trial eligibility criteria. Ineligible RW patients (18 %) had a poorer prognosis than eligible RW patients (82 %) and MOSAIC trial patients. The effectiveness of the comparator was modelled using MOSAIC trial results. All cost inputs were based on RW patients and reported in Euro 2012. Cost-effectiveness analyses were performed for four different scenarios: (1) cost-effectiveness analyses based on MOSAIC trial patients; (2) cost-effectiveness analyses using MOSAIC and eligible RW patients; (3) cost-effectiveness analyses using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had an equal effect in ineligible and eligible patients; (4) cost-effectiveness analyses using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had no effect amongst ineligibles. For each scenario, univariate and probabilistic sensitivity analyses were undertaken.
  
  
  RESULTS
  MOSAIC trial patients and eligible RW patients treated with oxaliplatin had comparable 2-year disease-free survivals (79.5 vs. 78.4 %). Oxaliplatin showed an incremental QALY gain of 1.02, 1.13, 1.17 and 0.93 and incremental cost of <euro>9,961, <euro>11,055, <euro>9,814 and <euro>11,854 in scenarios 1-4, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were <euro>9,766, <euro>9,783, <euro>8,388 and <euro>12,746 in scenarios 1-4, respectively. In all scenarios, univariate and probabilistic sensitivity analyses indicated that the ICERs are acceptable and robust under a wide range of model assumptions.
  
  
  CONCLUSIONS
  The ICERs of the different scenarios that resulted from combining MOSAIC trial data with data from Dutch daily practice all suggest that FL + oxaliplatin is cost-effective versus FL alone in the adjuvant treatment of colon cancer. This article illustrates how one could design and implement a real-world cost-effectiveness study to yield internally valid results that could also be generalisable.
authors: Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University, Burgemeester Oudlaan 50, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands. cwmvangils@gmail.com
authors: Chantal W M
authors: CW
authors: van Gils
authors: Saskia
authors: S
authors: de Groot
authors: William K
authors: WK
authors: Redekop
authors: Miriam
authors: M
authors: Koopman
authors: Cornelis J A
authors: CJ
authors: Punt
authors: Carin A
authors: CA
authors: Uyl-de Groot
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000191:economics / Q000627:therapeutic use*; D000077150:Oxaliplatin; D019057:Quality-Adjusted Life Years
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin
references: Curr Oncol. 2010 Feb;17(1):17-24
references: 20179799
references: Cancer. 2007 Mar 15;109(6):1082-9
references: 17265519
references: Ned Tijdschr Geneeskd. 2005 Jun 25;149(26):1441-7
references: 16010954
references: J Clin Oncol. 2004 Jun 1;22(11):2084-91
references: 15169795
references: Dis Colon Rectum. 1997 Jan;40(1):15-24
references: 9102255
references: Eur J Cancer. 2013 Jan;49(1):8-16
references: 22809557
references: J Intensive Care Med. 2008 Jul-Aug;23(4):250-7
references: 18508839
references: J Clin Oncol. 2009 Jul 1;27(19):3109-16
references: 19451431
references: J Natl Cancer Inst. 2011 Apr 20;103(8):689-97
references: 21421861
references: Eur J Cancer. 2013 Apr;49(6):1374-403
references: 23485231
references: N Engl J Med. 2009 Feb 5;360(6):563-72
references: 19196673
references: Value Health. 2012 Mar-Apr;15(2):255-60
references: 22433756
references: Eur J Cancer. 2007 Jul;43(11):1687-93
references: 17587564
references: Br J Cancer. 2006 Nov 6;95(9):1195-201
references: 17031407
references: Cancer. 2000 Mar 15;88(6):1294-303
references: 10717609
references: Lancet. 2005 Jan 1-7;365(9453):82-93
references: 15639683
references: N Engl J Med. 2005 Jun 30;352(26):2696-704
references: 15987918
references: Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185
references: 17049138
references: J Clin Oncol. 2012 Sep 20;30(27):3353-60
references: 22915656
references: Lancet. 1995 Apr 15;345(8955):939-44
references: 7715291
references: Cancer. 2004 Feb 1;100(3):531-7
references: 14745869
references: Ann Oncol. 2004 Oct;15(10):1453-9
references: 15367403
references: Am J Gastroenterol. 1999 Jun;94(6):1650-7
references: 10364039
references: J Clin Oncol. 2007 Jun 1;25(16):2198-204
references: 17470851
references: Acta Oncol. 2012 Jan;51(1):57-64
references: 22122695
references: Ann Intern Med. 1995 Mar 1;122(5):321-6
references: 7847642
references: N Engl J Med. 2004 Jun 3;350(23):2343-51
references: 15175436
references: Value Health. 2010 Sep-Oct;13(6):712-9
references: 20561330
references: N Engl J Med. 1990 Feb 8;322(6):352-8
references: 2300087